Product Manual
Table Of Contents
Procedural Notes
Remove the CareStar
The CareStart
The CareStart
,
Test Procedures
.
4
over the
collect the speci
3
Direct Swab Test Procedure
1
3
vial.
at least
2
4
5
PEEL OFF
CLICK
PUSH FIRMLY
TAP
7
10 min
Start the timer
Warning
Interpretaon of Results
NOTE:
Posive:
Negave:
Invalid:
Serial Tesng Results Reporng
NOTE:
NOTE:
F
.
G
must
room temperature.
Limitaons
The CareStart
CareStart™
CONDITIONS of AUTHORIZATION for LABORATORY
A
B
.
C.
D
E
CareStart
CareStart
method.
CareStart
Performance Characteriscs
Clinical Performance – Nasopharyngeal Swab
CareStart
CareStart
CareStart
d.
CareStart
CareStart™ COVID-19 Angen nasopharyngeal clinical performance
within 5 days of symptom onset against the comparator method
CareStart™ COVID-19 Angen
Posive
Negave
Total
Posive Percent Agreement (PPA)
Negave Percent Agreement (NPA)
Comparator
Posive Negave Total
- - -
Days
Since
Symptom
Onset
1 0 0
7 7
15 15
23 22
32 30
2
3
4
5
Cumulave RT-PCR
Posive
(+)
PPA 95% Confidence interval
Cumulave CareStart™
COVID-19 Angen
Posive (+)
1
Days
Since
Symptom
Onset
0 3 3
11 10
24 21
33 29
37 32
1
2
3
4
39 345
Cumulave RT-PCR
Posive
(+)
PPA 95% Confidence interval
Cumulave CareStart™
COVID-19 Angen
Posive (+)
Clinical Performance – Anterior Nasal Swab
CareStart™ COVID-19 Angen anterior nasal clinical performance
within 5 days of symptom onset against the comparator method
CareStart™ COVID-19 Angen
Posive
Negave
Total
Posive Percent Agreement (PPA)
Negave Percent Agreement (NPA)
Comparator
Posive Negave Total
Paent Demographics
Age Group
≤5 Years of Age
6-21 Years of Age
22-59 Years of Age
≥60 Years of Age
CareStart™ COVID-19 Angen
Total # Posive Prevalence
Endogenous Interfering Substances Effect
High-dose Hook Effect
in silico
-
CareStart
in silico
the CareStart
the CareStart
CareStart
The CareStart
Point of Care Use
The CareStart
the CareStart
Technical Support
Potenal Cross-Reactant
Potenal Interfering Substances Concentraon Potenal Interfering Substances Concentraon
50
Analycal Sensivity: Limit of Detecon (LoD)
the CareStart
-
CareStart™
tested
Analycal Specificity: Cross Reacvity (Exclusivity) and
Microbial Interference
7.95.2
50
50
The CareStart
CareStart
CareStart
Paent Demographics
Age Group
≤5 Years of Age
6-21 Years of Age
22-59 Years of Age
≥60 Years of Age
CareStart™ COVID-19 Angen
Total # Posive Prevalence
6
the sample are added.
90°
026.49
7.18 3.30
40




